This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jul;6(7):383.

doi: 10.1038/nrneph.2010.72.

Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial

PMID: 20597156
DOI: 10.1038/nrneph.2010.72

Comment

Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial

Baldo Lucchese. Nat Rev Nephrol. 2010 Jul.

. 2010 Jul;6(7):383.

doi: 10.1038/nrneph.2010.72.

Author

PMID: 20597156
DOI: 10.1038/nrneph.2010.72

No abstract available

PubMed Disclaimer

Comment on

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Ruilope LM, et al. Lancet. 2010 Apr 10;375(9722):1255-66. doi: 10.1016/S0140-6736(09)61966-8. Epub 2010 Mar 16. Lancet. 2010. PMID: 20236700 Clinical Trial.

References

1. Lancet. 2010 Apr 10;375(9722):1255-66 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.